Advertisement
ACIU vs KYTX
Which Stock Would AI Choose? AC Immune SA (ACIU) vs. Kyverna Therapeutics (KYTX) Stock Comparison
Key Takeaways
- ACIU is a clinical-stage biopharmaceutical focused on neurodegenerative diseases, while KYTX is a late-stage immunology company advancing CAR T-cell therapy for autoimmune diseases.
- Both stocks are down year-to-date, but KYTX carries a "Strong Buy" analyst consensus and a price target far above its recent trading range, reflecting higher perceived upside.
- ACIU's recent catalysts center on an FDA (U.S. Food and Drug Administration) Fast Track designation for its Parkinson's immunotherapy and partner-funded milestone revenue, while KYTX is advancing a rolling BLA (Biologics License Application) toward a potential 2027 commercial launch.
- Both companies remain pre-profitability, with cash runways into 2027 (ACIU) and 2028 (KYTX), making binary clinical and regulatory outcomes central to their risk profiles.
- For more context on each name, readers can explore ACIU Major News and ACIU Today's Price Move, as well as KYTX Major News and KYTX Today's Price Move.
- For an automated, data-driven view of these and other tickers, explore Trending AI Robots.
Introduction
This stock comparison examines two development-stage biotechnology companies operating at very different points along the drug-approval timeline. ACIU, or AC Immune SA, is a Swiss clinical-stage biopharmaceutical working on therapies and diagnostics for protein-misfolding diseases such as Alzheimer's and Parkinson's. KYTX, or Kyverna Therapeutics, is a late-stage immunology company pursuing CAR T-cell therapy (chimeric antigen receptor T-cell therapy, a treatment that reprograms a patient's own immune cells) for neurologic autoimmune conditions. Traders and investors weighing early-stage platform risk against nearer-term commercialization may find this relative performance and market positioning comparison particularly relevant.
ACIU Overview and Recent Performance
AC Immune focuses on neurodegenerative disease, with wholly owned programs targeting alpha-synuclein (in Parkinson's disease), the NLRP3 inflammasome, and TDP-43, alongside partnered programs with Takeda, Eli Lilly, and Janssen. In recent weeks, sentiment around ACIU has been shaped by regulatory and pipeline milestones: the FDA granted Fast Track designation to ACI-7104, its anti-alpha-synuclein immunotherapy for early Parkinson's disease, and cleared an IND (Investigational New Drug) application to expand its Phase 2 VacSYn study into U.S. sites. The company also reported a sharp rise in revenue driven by milestone payments under its amended Lilly agreement. Despite these catalysts, the stock has traded within a wide range and remains below earlier-year levels, reflecting ongoing investor caution around the historically high failure rate in dementia-related drug development and a CEO (chief executive officer) transition that introduced leadership uncertainty.
KYTX Overview and Recent Performance
Kyverna Therapeutics is advancing miv-cel (mivocabtagene autoleucel, KYV-101), a fully human CD19-targeting CAR T-cell therapy, across neurologic autoimmune diseases including stiff person syndrome (SPS) and generalized myasthenia gravis (gMG). Recent market activity has been driven by durable one-year trial data showing sustained mobility improvements and drug-free remission signals, as well as the start of a rolling BLA submission expected to be completed in the fourth quarter of 2026, with a potential commercial launch in 2027. The FDA also granted RMAT (Regenerative Medicine Advanced Therapy) designation for a progressive multiple sclerosis program. Even so, KYTX has pulled back year-to-date as investors digested data already reflected in prior rallies, and the company continues to fund its pipeline from a cash position expected to provide runway into 2028.
Trending AI Robots
For traders seeking a systematic alternative to manual stock selection, Tickeron's Trending AI Robots page curates a focused set of automated trading systems. Tickeron maintains hundreds of AI Trading Bots that collectively trade thousands of different tickers, but only a subset earns a place in this section. These featured robots are selected for their suitability to current market conditions, and each carries its own trading style, strategy, timeframe, performance history, and universe of tickers. This variety lets users compare bots across different risk profiles and holding periods rather than relying on a one-size-fits-all approach. Explore Trending AI Robots to review the currently highlighted strategies and their recent statistics.
Head-to-Head Comparison
Although both companies sit within biotechnology, their business models and risk-reward profiles differ meaningfully. ACIU operates an earlier-stage, partnership-heavy model, monetizing its discovery platform through milestone payments and royalties from large pharmaceutical collaborators while retaining select wholly owned programs. Its growth is tied to multiple early and mid-stage readouts across Alzheimer's and Parkinson's, areas with substantial unmet need but a well-documented history of clinical setbacks. KYTX, by contrast, is closer to a commercial inflection point, with a single lead asset pursuing a potential first approval in stiff person syndrome and an expanding multi-indication franchise. KYTX benefits from a clearer regulatory path and stronger sell-side conviction, while ACIU offers broader platform optionality but less near-term revenue visibility. On market sentiment, KYTX enjoys a more bullish analyst posture, whereas ACIU's narrative depends more heavily on discrete data catalysts and partner decisions.
Tickeron AI Verdict
Based on observable factors, Tickeron's AI would likely favor KYTX in the current environment, though with appropriate caution given both names' volatility. KYTX's positioning is supported by a more advanced regulatory timeline, a rolling BLA already underway, multiple RMAT designations, a longer cash runway, and a notably stronger analyst consensus. These factors suggest greater trend consistency and nearer-term catalyst clarity relative to ACIU, whose outlook depends on earlier-stage trial data and partnership execution. That said, the verdict is probabilistic rather than definitive: both stocks carry concentrated, binary risk, and relative positioning could shift quickly as new clinical or regulatory developments emerge.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ACIU is a StrongBuy and KYTX is a Hold.
ACIU's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for ACIU turned positive on November 09, 2026. Looking at past instances where ACIU's MACD turned positive, the stock continued to rise in 36 of 46 cases over the following month. The odds of a continued upward trend are 78%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where ACIU's RSI Oscillator exited the oversold zone, 21 of 27 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 78%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 45 of 68 cases where ACIU's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 66%.
Following a +15.64% 3-day Advance, the price is estimated to grow further. Considering data from situations where ACIU advanced for three days, in 164 of 224 cases, the price rose further within the following month. The odds of a continued upward trend are 73%.
ACIU may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 11, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ACIU as a result. In 75 of 86 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 87%.
The 10-day moving average for ACIU crossed bearishly below the 50-day moving average on October 09, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 16 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ACIU declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
The Aroon Indicator for ACIU entered a downward trend on November 11, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 44 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 67 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.304) is normal, around the industry mean (3.498). P/E Ratio (-5.186) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.070) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (12.547) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 74 (best 1 - 100 worst), indicating slightly worse than average price growth. ACIU’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ACIU’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
KYTX sees its Stochastic Oscillator climbs out of oversold territory
On November 10, 2026, the Stochastic Oscillator for KYTX moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 33 instances where the indicator left the oversold zone. In 31 of the 33 cases the stock moved higher in the following days. This puts the odds of a move higher at over 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where KYTX's RSI Indicator exited the oversold zone, 16 of 19 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 84%.
The Moving Average Convergence Divergence (MACD) for KYTX just turned positive on November 11, 2026. Looking at past instances where KYTX's MACD turned positive, the stock continued to rise in 20 of 24 cases over the following month. The odds of a continued upward trend are 83%.
Following a +12.15% 3-day Advance, the price is estimated to grow further. Considering data from situations where KYTX advanced for three days, in 122 of 137 cases, the price rose further within the following month. The odds of a continued upward trend are 89%.
KYTX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on KYTX as a result. In 43 of 52 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 83%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where KYTX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
The Aroon Indicator for KYTX entered a downward trend on November 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 14 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 79 (best 1 - 100 worst), indicating slightly worse than average price growth. KYTX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 89 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.823) is normal, around the industry mean (3.498). P/E Ratio (-1.671) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.658) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. KYTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
ACIU | ||
|---|---|---|
OUTLOOK RATING 1..100 | 64 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 67 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | |
SMR RATING 1..100 | 98 | |
PRICE GROWTH RATING 1..100 | 74 | |
P/E GROWTH RATING 1..100 | 44 | |
SEASONALITY SCORE 1..100 | 31 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| ACIU | KYTX | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 78% | 2 days ago 84% |
| Stochastic ODDS (%) | 2 days ago 66% | 2 days ago 90% |
| Momentum ODDS (%) | 2 days ago 87% | 2 days ago 83% |
| MACD ODDS (%) | 2 days ago 78% | 2 days ago 83% |
| TrendWeek ODDS (%) | 2 days ago 86% | 2 days ago 85% |
| TrendMonth ODDS (%) | 2 days ago 85% | 2 days ago 90% |
| Advances ODDS (%) | 6 days ago 73% | 6 days ago 89% |
| Declines ODDS (%) | 2 days ago 85% | 12 days ago 88% |
| BollingerBands ODDS (%) | 2 days ago 71% | 2 days ago 88% |
| Aroon ODDS (%) | 2 days ago 84% | 2 days ago 90% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ACIU’s FA Score shows that 0 FA rating(s) are green while KYTX’s FA Score has 1 green FA rating(s).
- ACIU’s FA Score: 0 green, 5 red.
- KYTX’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ACIU’s TA Score shows that 5 TA indicator(s) are bullish while KYTX’s TA Score has 5 bullish TA indicator(s).
- ACIU’s TA Score: 5 bullish, 4 bearish.
- KYTX’s TA Score: 5 bullish, 3 bearish.
Price Growth
ACIU (@Biotechnology) experienced а -4.48% price change this week, while KYTX (@Biotechnology) price change was +3.48% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -3.38%. For the same industry, the average monthly price growth was -5.88%, and the average quarterly price growth was -18.27%.
Reported Earning Dates
ACIU is expected to report earnings on Mar 18, 2027.
Industries' Descriptions
@Biotechnology (-3.38% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
ACIU and
Correlation & Price change
A.I.dvisor indicates that over the last year, ACIU has been loosely correlated with SANA. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if ACIU jumps, then SANA could also see price increases.
| Ticker / NAME | Correlation To ACIU | 1D Price Change % | ||
|---|---|---|---|---|
| ACIU | 100% | -0.47% | ||
| SANA - ACIU | 43% Loosely correlated | +0.50% | ||
| EDIT - ACIU | 42% Loosely correlated | +1.40% | ||
| KYTX - ACIU | 42% Loosely correlated | +0.40% | ||
| ALEC - ACIU | 41% Loosely correlated | +3.67% | ||
| BEAM - ACIU | 41% Loosely correlated | -4.99% | ||
More | ||||
KYTX and
Correlation & Price change
A.I.dvisor indicates that over the last year, KYTX has been loosely correlated with IMNM. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if KYTX jumps, then IMNM could also see price increases.
| Ticker / NAME | Correlation To KYTX | 1D Price Change % | ||
|---|---|---|---|---|
| KYTX | 100% | +0.40% | ||
| IMNM - KYTX | 59% Loosely correlated | +0.37% | ||
| FDMT - KYTX | 59% Loosely correlated | +0.95% | ||
| BNTC - KYTX | 53% Loosely correlated | -0.55% | ||
| SANA - KYTX | 49% Loosely correlated | +0.50% | ||
| TSHA - KYTX | 49% Loosely correlated | -2.61% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| HDV | 30.98 | 0.23 | +0.75% |
| iShares Core High Dividend ETF (HDV) | |||
| SFTX | 29.51 | -0.01 | -0.03% |
| Horizon International Managed Risk ETF (SFTX) | |||
| WOMN | 44.90 | -0.05 | -0.12% |
| Impact Shares Womens Empowerment ETF (WOMN) | |||
| HFGO | 26.43 | -0.27 | -1.01% |
| Hartford Large Cap Growth ETF | |||
| QBF | 16.06 | -0.38 | -2.32% |
| Innovator Uncapped Bitcoin 20 Floor ETF - Quarterly (QBF) | |||